GenomeDx Biosciences Inc

About GenomeDx Biosciences Inc

GenomeDx develops and commercializes transformative genomic tests that clarify decisions about the course of treatment for patients with urologic cancers. Our first test, Decipher™, provides a direct measure of the true biological risk of prostate cancer metastasis in patients following radical prostatectomy. This measure is specific to metastasis and – more... 

Claimed Profile